Medical Condition News

RSS

Two-day international Osteoarthritis Summit to be held in June 2011

Hospital for Special Surgery (HSS) plans to host a two-day international Osteoarthritis Summit in June 2011. The Hospital, internationally recognized for its leadership in the fields of orthopedics and rheumatology, will bring together, for the first time, a truly comprehensive multidisciplinary group of world renowned scientists, thought-leaders and industry representatives from the United States, Canada, and Europe, to discuss all aspects of OA and develop a consensus document on future directions for OA research, prevention and treatment.

3 Jul 2010

Neogenix Oncology files patent application with USPTO for 16C3 antigen

Neogenix Oncology announced today that the company has filed a patent application with the U.S. Patent and Trade Office (USPTO) for the 16C3 antigen. The Company believes that this antigen is tumor specific for pancreatic and colorectal tumors; and, based on preliminary clinical data, may also have diagnostic utility as a biomarker for these cancers.

3 Jul 2010

Fera Pharmaceuticals launches Neptazanetm tablets for reducing intraocular pressure

Fera Pharmaceuticals is pleased to announce the launch of Neptazane (Methazolamide) 25 mg and 50 mg tablets. Both strengths are available in 90 count bottles.

3 Jul 2010

People with high levels of vitamin B6 and methionine less likiely to develop lung cancer

People with higher blood levels of vitamin B6 and the amino acid methionine appear to have a lower risk of lung cancer, a French study has found. But more research is needed to understand if higher levels of the nutrients directly protect against the disease.

3 Jul 2010

Lawmakers urge health insurers to enforce new Mental Parity Act

The Hill: "Health plans that say mental illnesses can't be treated like physical ailments are relying on an 'outdated argument' without merit that does not reflect 'three decades of scientific research,' 52 House members wrote in a recent letter to regulators. The comments come as a landmark law requiring parity in how health plans cover physical and mental illness went into effect Thursday.

3 Jul 2010

Research finds strong relationship between food environment, built environment and obesity

Researchers at the University at Buffalo conducting a neighborhood-scaled exploratory study that tested the association between the food environment, the built environment and women's body mass index (BMI) have found that women with homes closer to a supermarket, relative to a convenience store, had lower BMIs, and that the greater the number of restaurants within a five minute walk of a woman's home, the higher her BMI.

3 Jul 2010

Blacks five times more prone to hypertension than Whites

The hospital admission rate for Blacks with hypertension was 161 per 100,000 people in 2006 - nearly 5 times the hospitalization rate for Whites (33 admissions per 100,000), according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

3 Jul 2010

Impax confirms challenge of patent relating to RENVELA

Impax Laboratories, Inc. today confirms that it has initiated a challenge of a patent listed by Genzyme Corporation in connection with RENVELA® (sevelamer carbonate for suspension), 2.4 g and 0.8 g.

3 Jul 2010

WHO Fracture Risk Assessment Tool version 3.1 launched

The WHO Fracture Risk Assessment Tool (FRAX-) has today been launched in version 3.1., featuring eight new country models and accessible in six additional languages.

3 Jul 2010

Strativa receives FDA approval for Zuplenz oral soluble film

Strativa Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved Zuplenz® (ondansetron) oral soluble film for the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting. Zuplenz, a unique formulation of ondansetron, is the first oral soluble film approved by the FDA as a prescription medication.

3 Jul 2010

Watson Laboratories receives FDA approval for Tacrolimus ANDA

Watson Pharmaceuticals, Inc., today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Tacrolimus 5 mg capsules, the generic equivalent to Astellas' Prograf® capsules.

2 Jul 2010

Studies demonstrate analgesic properties of synthetic cannabinoid

A new compound similar to the active component of marijuana (cannabis) might provide effective pain relief without the mental and physical side effects of cannabis, according to a study in the July issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

2 Jul 2010

Study: ONGLYZA and metformin improve HbA1c levels for adult patients with type 2 diabetes at 76-weeks

Bristol-Myers Squibb Company and AstraZeneca today announced results up to 76-weeks from a Phase 3 study of ONGLYZA(TM) (saxagliptin) as initial combination therapy with metformin, which produced long-term glycemic improvement (as measured by glycosylated hemoglobin level (HbA1c)) in treatment-naive adults with type 2 diabetes mellitus inadequately controlled on diet and exercise compared to treatment with an investigational 10 mg dose of saxagliptin or metformin alone.

2 Jul 2010

Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients

Shire plc, the global specialty biopharmaceutical company, today announced positive data from its long-term extension to its open label Phase I/II study (TKT-025 EXT) for VPRIV® (velaglucerase alfa), the company's enzyme replacement therapy for patients with type 1 Gaucher disease. The data were presented at the 9th Annual European Working Group on Gaucher Disease (EWGGD) in Cologne, Germany, and add to the growing body of clinical evidence which supports the safety and sustained efficacy of VPRIV.

2 Jul 2010

Sensor-augmented insulin-pump therapy effective for type 1 diabetes patients

Adding a continuous blood sugar level sensor to an insulin pump helps patients with type 1 diabetes achieve better blood sugar control compared to the common standard of care, multiple daily insulin injections, concludes a study published on-line today in the New England Journal of Medicine.

2 Jul 2010

Twelve type 2 diabetes susceptibility loci identified

An international team co-led by scientists from the University of Michigan have discovered 12 more regions on the genome with DNA variants that are associated with increased risk of type 2 diabetes, bringing the number to 38.

2 Jul 2010

Chelsea reports positive outcome from DMC review of droxidopa Phase II trial in fibromyalgia

Chelsea Therapeutics International, Ltd. announced the completion and favorable outcome of an independent Data Monitoring Committee (DMC) review of the safety and efficacy data from approximately half the target enrollment in Chelsea's Phase II trial of droxidopa in fibromyalgia.

2 Jul 2010

Visually impaired people dose accurately with insulin pens: Study

Labels on the popular insulin pen used by people with diabetes warn against visually-impaired people using pens to measure out and administer their insulin dosage.

2 Jul 2010

ISHLT issues first international consensus formulation of standardized nomenclature for CAV

Cardiac allograft vasculopathy (CAV), the major limitation to long term survival after heart transplantation, occurs when blood vessels in a transplanted heart progressively narrow and lead to dysfunction of the heart muscle or sudden death. Ascertaining benefit from appropriate treatment for this condition has been hampered in part because of the lack of a standard nomenclature.

2 Jul 2010

QR Pharma to present clinical data from mechanism of action study in MCI patients at ICAD 2010

QR Pharma, Inc., a developer of novel drugs to treat Alzheimer's disease (AD), announced today that it has been accepted to present a poster on clinical data from its recent mechanism of action study in mild cognitive impaired (MCI) patients at the International Congress on Alzheimer's Disease (ICAD 2010).

2 Jul 2010

Medical Condition News

Two-day international Osteoarthritis Summit to be held in June 2011

Neogenix Oncology files patent application with USPTO for 16C3 antigen

Fera Pharmaceuticals launches Neptazanetm tablets for reducing intraocular pressure

People with high levels of vitamin B6 and methionine less likiely to develop lung cancer

Lawmakers urge health insurers to enforce new Mental Parity Act

Research finds strong relationship between food environment, built environment and obesity

Blacks five times more prone to hypertension than Whites

Impax confirms challenge of patent relating to RENVELA

WHO Fracture Risk Assessment Tool version 3.1 launched

Strativa receives FDA approval for Zuplenz oral soluble film

Watson Laboratories receives FDA approval for Tacrolimus ANDA

Studies demonstrate analgesic properties of synthetic cannabinoid

Study: ONGLYZA and metformin improve HbA1c levels for adult patients with type 2 diabetes at 76-weeks

Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients

Sensor-augmented insulin-pump therapy effective for type 1 diabetes patients

Twelve type 2 diabetes susceptibility loci identified

Chelsea reports positive outcome from DMC review of droxidopa Phase II trial in fibromyalgia

Visually impaired people dose accurately with insulin pens: Study

ISHLT issues first international consensus formulation of standardized nomenclature for CAV

QR Pharma to present clinical data from mechanism of action study in MCI patients at ICAD 2010

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Latest News